article thumbnail

STAT+: An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

STAT

But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world.

article thumbnail

‘What a gift to give’: For a woman struggling with infertility, a sister’s unexpected offer of surrogacy brings new hope

STAT

After the brain tumor diagnosis in 2016, Gatton would undergo two brain surgeries, radiation treatment, chemotherapy, followed by an embryo transfer that failed. Gatton and her husband had struggled to conceive naturally for years and completed six unsuccessful intrauterine inseminations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NICE guidance recommends olaparib for breast and prostate cancers

European Pharmaceutical Review

For breast cancer patients, the treatment is approved for those who have inherited faults in their BRCA1 or BRCA2 genes, after surgery and chemotherapy and are HER2-negative and at high-risk. Additionally, this means NICE has now made positive recommendations in all 19 of its appraisals of breast cancer treatments since 2016.

article thumbnail

First CAR T-cell therapy recommended on NHS

European Pharmaceutical Review

After initial chemotherapy, up to 45 percent of patients with DLBCL will require a second line treatment, which often involves high dose chemotherapy and a stem cell transplant, according to a guideline published in a 2016 issue of the British Journal of Haematology. Could CAR T therapies be manufactured in one day?

article thumbnail

Bid to expand Keytruda use in head and neck cancer therapy fails

pharmaphorum

Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced disease, i.e. recurrent or relapsed HNSCC that has metastasised to other parts of the body.

article thumbnail

Roche’s Tecentriq loses bladder cancer use as FDA crackdown continues

pharmaphorum

The Swiss pharma said it is voluntarily withdrawing the US indication for the immunotherapy Tecentriq (atezolizumab) in metastatic urothelial carcinoma (mUC) previously treated with chemotherapy.

FDA 98
article thumbnail

Targeting ovarian cancer with a novel antibody therapeutic

European Pharmaceutical Review

This authorisation of the antibody drug conjugate Elahere provides a much needed clinically meaningful option for women living with this type of ovarian cancer, whose disease returns because they develop resistance to platinum-based chemotherapy regimens. She joined AbbVie in 2016, as Head of Medical Affairs, Canada. AbbVie agrees $1.4